FTC Sues Endo Pharmaceuticals and Generic Manufacturers over Pay-for-Delay Agreements | Practical Law
The Federal Trade Commission (FTC) sued Endo Pharmaceuticals Inc. and several generic drug manufacturers over alleged pay-for-delay agreements for drugs Opana ER and Liboderm. The FTC argued that the agreements, which delayed consumer access to generic versions of the drugs, cost consumers hundreds of millions of dollars.